首页> 外文OA文献 >Targeting the Iron-Response Elements of the mRNAs for the Alzheimer’s Amyloid Precursor Protein and Ferritin to Treat Acute Lead and Manganese Neurotoxicity
【2h】

Targeting the Iron-Response Elements of the mRNAs for the Alzheimer’s Amyloid Precursor Protein and Ferritin to Treat Acute Lead and Manganese Neurotoxicity

机译:针对阿尔茨海默氏蛋白前体蛋白和铁蛋白的MRNA的铁反应元素治疗急性铅和锰神经毒性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The therapeutic value of inhibiting translation of the amyloid precursor protein (APP) offers the possibility to reduce neurotoxic amyloid formation, particularly in cases of familial Alzheimer’s disease (AD) caused by APP gene duplications (Dup⁻APP) and in aging Down syndrome individuals. APP mRNA translation inhibitors such as the anticholinesterase phenserine, and high throughput screened molecules, selectively inhibited the uniquely folded iron-response element (IRE) sequences in the 5’untranslated region (5’UTR) of APP mRNA and this class of drug continues to be tested in a clinical trial as an anti-amyloid treatment for AD. By contrast, in younger age groups, APP expression is not associated with amyloidosis, instead it acts solely as a neuroprotectant while facilitating cellular ferroportin-dependent iron efflux. We have reported that the environmental metallotoxins Lead (Pb) and manganese (Mn) cause neuronal death by interfering with IRE dependent translation of APP and ferritin. The loss of these iron homeostatic neuroprotectants thereby caused an embargo of iron (Fe) export from neurons as associated with excess unstored intracellular iron and the formation of toxic reactive oxidative species (ROS). We propose that APP 5’UTR directed translation activators can be employed therapeutically to protect neurons exposed to high acute Pb and/or Mn exposure. Certainly, high potency APP translation activators, exemplified by the Food and Drug Administration (FDA) pre-approved M1 muscarinic agonist AF102B and high throughput-screened APP 5’UTR translation activators, are available for drug development to treat acute toxicity caused by Pb/Mn exposure to neurons. We conclude that APP translation activators can be predicted to prevent acute metal toxicity to neurons by a mechanism related to the 5’UTR specific yohimbine which binds and targets the canonical IRE RNA stem loop as an H-ferritin translation activator.
机译:抑制淀粉样前体蛋白(APP)的平移治疗价值提供了降低神经毒性淀粉样蛋白形成,特别是在引起APP基因重复(Dup⁻APP),并在老化唐氏综合征的个体家族性阿尔茨海默病(AD)的情况的可能性。 APP mRNA的翻译抑制剂,诸如抗胆碱酯酶的phenserine,和高通量筛选的分子,其选择性地抑制了唯一地折叠铁响应元件在5'非翻译区APP的mRNA(5'UTR)(IRE)序列和此类的药物继续在临床试验中作为抗淀粉样蛋白治疗AD进行测试。相反,在年轻的年龄组,APP表达不与淀粉样变性相关,而是只作为神经保护剂而促进细胞膜铁转运蛋白依赖性铁流出。我们已经报道了环境metallotoxins铅(Pb),锰(Mn)的病因的神经元死亡与APP的IRE依赖翻译和铁的干扰。这些铁稳态神经保护的损失从而如用过量的未存储的细胞内铁和有毒活性氧物种(ROS)的形成相关联的引起铁(Fe)的出口的禁运从神经元。我们建议,APP 5'UTR制导翻译激活剂可以治疗上采用暴露于高铅急性和/或锰暴露保护神经元。当然,高效力APP翻译活化剂,由美国食品和药物管理局(FDA)批准预售M1毒蕈碱型激动剂AF102B和高通量筛选APP 5'UTR翻译活化剂,可用于药物开发所造成的铅治疗急性毒性例证/锰暴露于神经元。我们的结论是APP的翻译活化剂可以预测,以防止急性毒性金属对神经元相关的特定5'UTR育亨宾,其结合和目标规范IRE RNA茎环作为H-铁蛋白翻译活化剂的机构。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号